|
NR. 2/2008
|
|
|
|
|
|
|
|
|
Implanty
doszklistkowe w leczeniu zapalenia błony naczyniowej
Intravitreal Implants in the Uveitis Treament
Małgorzata Iwanejko, Marta
Misiuk-Hojło
Katedra i Klinika Okulistyki Akademii Medycznej we Wrocławiu
Kierownik: prof. nzw. dr hab. n. med. Marta Misiuk-Hojło |
|
|
|
|
|
|
|
| Summary: |
Uveitis is potentially
sight-threatening inflammatory eye disease caused by
infectious and non-infectious factors for which the
standard care involves corticosteroids or immunomodulary
therapy (IMT) medicines. Some patients have disease
relapse in spite of local and systemic treatment. Poor
control of inflammatory episodes caused by medicine dose
reduction to minimum because of their side effects, may
lead to frequent disease relapses resulting in
cumulative damage – which may lead to cystoid macular
edema (CME), retinal detachment, glaucoma and cataract.
The goal of the treatment should not only be to suppress
inflammation but also to achieve sustained inflammation
control until its complete remission and thus prevent
permanent cumulative damage. For the last years,
intravitreal implants containing fluocinolone acetonide,
corticosteroid with slow release has been used in
uveitis treatment providing sustained inflammation
control and allowing local and systemic therapies
reduction or elimination. The main indication for
implantation is non-infectious uveitis affecting the
posterior segment of the eye. The most common implant
side effect is increased intraocular pressure and
cataract development. In the study, slowly released
fluocinolone acetonide reduced inflammation recurrences
and improved or stabilized visual acuity. Intravitreal
implant with corticosteroid is effective uveitis
treatment and may help to prevent cumulative damage and
vision loss. |
| |
|
| Key words: |
uveitis, treatment,
intravitreal implant. |
|
|
|
|
|
|
|
|
